Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 17
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Scienture Holdings Inc
SCNX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.99
0.09
3.1%
In chiusura: Nov 13, 4:00 PM EST
$2.91
0.01
0.34%
Pre-mercato: 4:00 AM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Dividendi
Confronta
Rapporto azionario
Utili:
I risultati di Q3 2026 sono stati pubblicati in data lun nov 16th, prima dell'apertura del mercato
Scienture Holdings Financials
Scienture Holdings (SCNX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Scienture Holdings Q3 EPS $(3.76) Misses $(1.57) Estimate, Sales $1.255M Beat $1.220M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(3.76) per share which missed the analyst consensus estimate of $(1.57) by 139.49 percent. This is a 21.01 percent increase over losses of $(4.76) per share
Benzinga Newsdesk
PRO
Scienture Holdings Reports Preliminary Q3 Revenue Growth To $1.22M; Co Targeting Profitability In 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™Two FDA-Approved Commercial Products
Benzinga Newsdesk
PRO
SCIENTURE HOLDINGS Reports Preliminary Q3 Revenue Of ~$1.22M
SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers
Benzinga Newsdesk
PRO
EXCLUSIVE: Scienture Reports Preliminary Q3 Sales of ~$1.22M, Sequential Growth of 256%, Arbli Wholesale Unit Sales Increased 74% Sequentially
Benzinga Newsdesk
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.
Vandana Singh
PRO
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 85.42 percent increase over losses of $(0.48) per share
Benzinga Newsdesk